80/100BEli Lilly & Co stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Eli Lilly & Co is 1,445.12, 0.5% above the current price of 1,438.17. Their targets range from 940.00 to 1,650.00.
Of the 22 firms that rated Eli Lilly & Co in the past 12 months, 21 rate it buy or strong buy, 0 hold and 1 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 940.00 to 1,650.00, with an average of 1,445.12.
| Buy | 21 | |
| Hold | 0 | |
| Sell | 1 |
12-month price target
| Highest target | 1,650.00 |
| Average target | 1,445.12 |
| Lowest target | 940.00 |
| Current price | 1,438.17 |
Eli Lilly & Co price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Eli Lilly & Co price target and rating?
How analysts rate Eli Lilly & Co, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
21 of 22 firms rate it buy now, against 14 of 18 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Eli Lilly & Co analyst upgrades, downgrades and price targets
The latest rating change came on 17 March 2026, when HSBC downgraded Eli Lilly & Co from Hold to Reduce. The most recent new target came from Cantor Fitzgerald on 2 November 2026: 1,600.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 2 Nov 2026 | Cantor Fitzgerald Carter Gould | Reiterated · Overweight | 1,440.00 → 1,600.00 | +11.1% | 1,409.22 |
| 30 Oct 2026 | RBC Capital | Reiterated · Outperform | 1,500.00 → 1,600.00 | +6.7% | 1,425.34 |
| 30 Oct 2026 | Argus Research Jasper Hellweg | Reiterated · Buy | 1,550.00 | — | 1,373.00 |
| 30 Oct 2026 | UBS Michael Yee | Reiterated · Buy | 1,376.00 → 1,625.00 | +18.1% | 1,373.00 |
| 30 Oct 2026 | BMO Capital Evan Seigerman | — | 1,400.00 → 1,650.00 | +17.9% | 1,373.00 |
| 30 Oct 2026 | KeyBanc | — | 1,497.00 | — | 1,373.00 |
| 30 Oct 2026 | Wells Fargo Mohit Bansal | Reiterated · Overweight | 1,330.00 → 1,500.00 | +12.8% | 1,373.00 |
| 30 Oct 2026 | Truist Financial Srikripa Devarakonda | Reiterated · Buy | 1,370.00 → 1,612.00 | +17.7% | 1,373.00 |
| 26 Oct 2026 | Bernstein Courtney Breen | — | 1,385.00 → 1,450.00 | +4.7% | 1,273.46 |
| 21 Oct 2026 | Leerink Partners | Reiterated · Outperform | 1,232.00 → 1,316.00 | +6.8% | 1,265.92 |
| 20 Oct 2026 | Goldman Sachs | — | 1,260.00 → 1,413.00 | +12.1% | 1,300.46 |
| 8 Oct 2026 | Cantor Fitzgerald Carter Gould | Reiterated · Overweight | 1,410.00 → 1,440.00 | +2.1% | 1,188.72 |
| 7 Oct 2026 | Morgan Stanley | Reiterated · Overweight | 1,419.00 → 1,430.00 | +0.8% | 1,184.48 |
| 18 Sept 2026 | Guggenheim Seamus Fernandez | Reiterated · Buy | 1,273.00 → 1,284.00 | +0.9% | 1,152.13 |
| 15 Sept 2026 | Berenberg Bank Kerry Holford | — | 1,135.00 → 1,400.00 | +23.3% | 1,137.75 |
| 10 Sept 2026 | HSBC | Reiterated · Reduce | 1,251.00 → 940.00 | -24.9% | 1,124.16 |
| 7 Aug 2026 | UBS | — | 1,425.00 → 1,376.00 | -3.4% | 1,177.33 |
| 6 Aug 2026 | Cantor Fitzgerald | Reiterated · Overweight | 1,350.00 → 1,410.00 | +4.4% | 1,181.00 |
| 6 Aug 2026 | Morgan Stanley | — | 1,347.00 → 1,419.00 | +5.3% | 1,169.86 |
| 6 Aug 2026 | Wells Fargo Mohit Bansal | Reiterated · Overweight | 1,280.00 → 1,330.00 | +3.9% | 1,169.86 |
| 6 Aug 2026 | BMO Capital Evan Seigerman | — | 1,300.00 → 1,400.00 | +7.7% | 1,169.86 |
| 14 Jul 2026 | Bernstein | Reiterated · Outperform | 1,300.00 → 1,385.00 | +6.5% | 1,185.08 |
| 13 Jul 2026 | UBS | Reiterated · Buy | 1,370.00 → 1,425.00 | +4.0% | 1,189.91 |
| 13 Jul 2026 | Guggenheim | Reiterated · Buy | 1,161.00 → 1,273.00 | +9.6% | 1,188.58 |
| 9 Jul 2026 | UBS | — | 1,250.00 → 1,370.00 | +9.6% | 1,222.13 |
| 8 Jul 2026 | Truist Financial | Reiterated · Buy | 1,281.00 → 1,370.00 | +6.9% | 1,227.07 |
| 8 Jul 2026 | RBC Capital | Reiterated · Outperform | 1,250.00 → 1,500.00 | +20.0% | 1,229.22 |
| 8 Jul 2026 | Morgan Stanley Terence Flynn | Reiterated · Overweight | 1,344.00 → 1,347.00 | +0.2% | 1,235.56 |
| 6 Jul 2026 | Cantor Fitzgerald | Reiterated · Overweight | 1,230.00 → 1,350.00 | +9.8% | 1,210.50 |
| 25 Jun 2026 | Leerink Partners David Risinger | Reiterated · Outperform | 1,119.00 → 1,232.00 | +10.1% | 1,117.26 |
| 22 Jun 2026 | Berenberg Bank Kerry Holford | — | 830.00 → 1,135.00 | +36.7% | 1,111.67 |
| 9 Jun 2026 | Jefferies | Reiterated · Buy | 1,300.00 → 1,350.00 | +3.8% | 1,143.35 |
| 26 May 2026 | HSBC | — | 1,070.00 → 1,251.00 | +16.9% | 1,065.00 |
| 26 May 2026 | Leerink Partners David Risinger | — | 1,234.00 → 1,119.00 | -9.3% | 1,065.00 |
| 21 May 2026 | Wolfe Research | — | 1,350.00 | — | 1,037.82 |
| 5 May 2026 | Barclays Emily Field | Reiterated · Overweight | 1,350.00 → 1,400.00 | +3.7% | 967.93 |
| 1 May 2026 | Morgan Stanley | — | 1,327.00 → 1,344.00 | +1.3% | 961.56 |
| 1 May 2026 | Cantor Fitzgerald Carter Gould | Reiterated · Overweight | 985.00 → 1,230.00 | +24.9% | 970.68 |
| 10 Apr 2026 | Morgan Stanley | Reiterated · Overweight | 1,313.00 → 1,327.00 | +1.1% | 939.31 |
| 17 Mar 2026 | HSBC | Downgraded · Hold → Reduce | — | — | — |
| 13 Mar 2026 | Jefferies Akash Tewari | — | 1,300.00 | — | 1,000.78 |
| 6 Mar 2026 | Deutsche Bank James Shin | — | 1,285.00 | — | 990.31 |
| 5 Mar 2026 | Morgan Stanley Terence Flynn | — | 1,290.00 → 1,313.00 | +1.8% | 972.50 |
| 24 Feb 2026 | RBC Capital Trung Huynh | — | 1,250.00 | — | 1,042.15 |
| 19 Feb 2026 | Barclays | — | 1,350.00 | — | 1,023.22 |
| 10 Feb 2026 | Loop Capital Markets Ilya Zubkov | — | 950.00 → 1,200.00 | +26.3% | 1,025.00 |
| 10 Feb 2026 | Freedom Broker | Upgraded · Hold → Buy | — | — | — |
| 5 Feb 2026 | Scotiabank | — | 1,300.00 | — | 1,037.13 |
| 5 Feb 2026 | Truist Financial | — | 1,182.00 → 1,281.00 | +8.4% | 1,027.51 |
| 5 Feb 2026 | Goldman Sachs | — | 1,145.00 → 1,260.00 | +10.0% | 1,107.12 |
Eli Lilly & Co EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Eli Lilly & Co's EPS to grow 35.6% a year until 2028. Over the last 5 years it grew 28.8% a year, and over the last 3 years 49.3%.
Analysts expect Eli Lilly & Co's revenue to grow 22.1% a year until 2028. Over the last 5 years it grew 21.6% a year, and over the last 3 years 31.7%.
Revenue
EPS
Does Eli Lilly & Co beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 18.8% off the result, either way, and their revenue estimate 7.1%, over the last 12 quarters.
- EPS beats
- 86 / 136
- Revenue beats
- 78 / 119
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +15.5%
- Since
- February 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 29 Oct 2026 | 5.71 | 7.48 | +31.0% | 22.58B | 24.40B | +8.0% |
| Q2 FY2026 | 5 Aug 2026 | 6.40 | 8.38 | +30.9% | 20.82B | 22.97B | +10.3% |
| Q1 FY2026 | 30 Apr 2026 | 6.97 | 8.55 | +22.7% | 17.82B | 19.80B | +11.1% |
| Q4 FY2025 | 4 Feb 2026 | 6.91 | 7.54 | +9.1% | 17.94B | 19.29B | +7.5% |
| Q3 FY2025 | 30 Oct 2025 | 5.69 | 7.02 | +23.4% | 16.05B | 17.60B | +9.6% |
| Q2 FY2025 | 7 Aug 2025 | 5.60 | 6.31 | +12.7% | 14.70B | 15.56B | +5.8% |
| Q1 FY2025 | 1 May 2025 | 3.26 | 3.34 | +2.5% | 12.67B | 12.73B | +0.5% |
| Q4 FY2024 | 6 Feb 2025 | 5.03 | 5.32 | +5.8% | — | 13.53B | — |
| Q3 FY2024 | 30 Oct 2024 | 1.47 | 1.18 | -19.7% | 12.10B | 11.44B | -5.4% |
| Q2 FY2024 | 8 Aug 2024 | 2.60 | 3.92 | +50.8% | 9.98B | 11.30B | +13.2% |
| Q1 FY2024 | 30 Apr 2024 | 2.46 | 2.58 | +4.9% | 8.94B | 8.77B | -1.9% |
| Q4 FY2023 | 6 Feb 2024 | 2.22 | 2.49 | +12.2% | 8.93B | 9.35B | +4.7% |
Eli Lilly & Co stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Eli Lilly & Co's earnings grow at the 33.2% a year analysts expect to FY2028, then 15.0% a year, it would earn about 75.69 a share in FY2030. At the P/E it has traded at over the last five years (46.6 to 55.7) that is 3,523.76 to 4,214.44 a share, or 3,709.39 at its average P/E of 49.0. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 35.36 | 1,646.27 | 1,732.99 | 1,968.95 |
| FY2027 | 50.25 | 2,339.34 | 2,462.58 | 2,797.87 |
| FY2028 | 57.23 | 2,664.47 | 2,804.83 | 3,186.72 |
| FY2029 (extrapolated) | 65.81 | 3,064.14 | 3,225.56 | 3,664.73 |
| FY2030 (extrapolated) | 75.69 | 3,523.76 | 3,709.39 | 4,214.44 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 15.0% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (46.6, 49.0, 55.7).
Is Eli Lilly & Co stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Eli Lilly & Co's P/E of 46.6 is below the middle of its 5-year range (33.1 to 148.6, median 55.4). Analysts expect slower growth than in recent years, so the low P/E may be deserved. Buyers pay less for each point of growth than usual: a PEG of 1.3 on expected growth against 1.9 on its median P/E and past five years' growth. At its usual P/E (41.7 × EPS of 30.89), Eli Lilly & Co's fair value is 1,289.63; the price, 1,438.17, is 11.5% above it. Its forward P/E, on the consensus for FY2026, is 40.7.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (33.1 and 54.1). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 46.56
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 55.41
- Five-year P/E range
- 33.1 – 148.6
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 40.67
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 1.40
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +0.5%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 64.525 | 127.9762Price 64.53185 | +98.3% | |
| 28.410 | 56.3234Price 28.4196 | +98.2% | |
| 153.725 | 297.58169Price 153.73471 | +93.6% | |
| 243.002 | 464.71205Price 243.00627 | +91.2% | |
| 160.085 | 305.52160Price 160.09396 | +90.8% | |
| 37.565 | 71.4258Price 37.57193 | +90.1% | |
| 160.240 | 300.28225Price 160.24375 | +87.4% |
Furthest below the fair value on each stock's page, updated every day.